We stand with our patients and against H.R. 2905
Medicare patients with CIDP or MMN currently have the option to utilize either:
- Medicare Part D benefits to receive home infusion of intravenous immune globulin (IVIG), or
- Medicare Part B benefits to receive infusion of IVIG in the hospital outpatient setting
Home infusion is an important option for patients
- Who live far from hospital outpatient infusion centers
- With transportation or ambulation challenges
- When hospital infusion centers have scheduling limitations
- With challenging work or family schedules
- Who are elderly
- Who are immunocompromised
- Will eliminate the Medicare Part D home infusion benefit for CIDP and MMN patients who need IVIG
- Will shift the IVIG home infusion benefit to Medicare Part B for CIDP and MMN patients
If H.R. 2905 is passed
- Home infusion of IVIG for Medicare CIDP and MMN patients will be severely limited or eliminated as a treatment option
• Medicare B reimbursement for IVIG is less than the acquisition cost of IVIG for home infusion providers
- Medicare CIDP and MMN patients will be treated at a higher-cost hospital outpatient site or
- Medicare CIDP and MMN patients will self-infuse a higher-cost subcutaneous product
- Access to IVIG treatment for Medicare CIDP and MMN patients will be compromised
We, the undersigned, support our patients’ access to home infusion of IVIG and strongly oppose the Medicare IVIG Access Enhancement Act (H.R.2905).
We urge you to vote against this harmful bill.
For additional information, please contact Sohail Masood, PharmD at (781) 777-3630.